Impact of highly active antiretroviral therapy on liver function of under-five HIV-positive children in Southern Nigeria
Main Article Content
Abstract
Background: Hepatotoxicity deserves serious attention due to mortality, morbidity and treatment discontinuation in HIV-seropositive patients.
Objectives: The study aimed at evaluating the impacts of Highly Active Antiretroviral Therapy (HAART) on liver function of under-five children in Southern Nigeria.
Method: In five hospitals, 238 under-five children were enrolled after ethical permission was received from Ethics and Research committees and written consent were obtained from participants' care-givers. Participants were divided into six groups: the HIV-seropositive either on HAART (group A, n= 91) or cotrimoxazole (group B, n= 11) and four other groups who were HIV-seronegative. Among this second cohort were those commenced on nevirapine for six weeks post-exposure (group C1, n= 24) and co-trimoxazole at 6 months (group C2, n= 18) or 18 months (group C3, n= 48) post-exposure. The last group received no medication (group D, n= 46). Initially, a blood sample of 2ml was obtained from each participant and was assayed for alanine aminotransferase (ALT) and aspartate aminotransferase (AST). After three- and six-months from the time of initial study, only group A participants were restudied for the liver enzymes' assay. Body mass index of the participants were also determined. Mean and standard deviation of the parameters of participants in group A was compared with those from other groups by using ANOVA. The differences in the parameters were considered significant at p≤0.05.
Results: Alanine aminotransferase (ALT) was significantly higher in group A compared to group B (12.8±11.0 IU/L vs 6.5±2.6 IU/L, p= 0.245), group C1 (12.8±11.0 IU/L vs 10.9±7.8 IU/L, p= 0.910), group C2 (12.8±11.0 IU/L vs 11.7±20.7 IU/L, p= 0.995), group C3 (12.8±11.0 IU/L vs 11.2±6.9 IU/L, p= 0.868), and group D (12.8±11.0 IU/L vs 5.8±3.4 IU/L, p= 0.001). After three and six months of monitoring, ALT of group A was significantly decreased by 39.3% (p= 0.001) and 50.6% (p= 0.000) respectively.
Conclusion: The elevated ALT of under-five HIV-infected children on HAART lowered after six months of monitoring.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Aledort JE, Ronald A, Le Blancq SM, Ridzon R, Landay A, Rafael ME, Shea MV, Safrit J, Peeling RW, Hellmann N, Mwaba P, Holmes K and Wilfert C (2006). Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature 444: S119-128.
Joint United Nations Programme on HIV/AIDS (2010). Overview of the global AIDS epidemic. UN report on the global AIDS epidemic 2010. ISBN 978-92-9173-871-7.http://www.unaids.org/globalreport/Global_report.htm. Accessed March 14, 2014.
Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ and Holmberg SD (1998). Declining morbidity and
mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338: 853-860.
Lukas GM, Chaisson RE and Moore RD (1999). Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and
adverse drug reactions. Annals of International Medicine 131: 81-87.
Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, Tomasoni L, Quiros-Roldan E, Favret M, Berchich L, Grigolato P, Callea F and Carosi G for the HIV-HCV co-infection Study Group (2003). Severe hepatotoxicity during combination antiretroviral treatment: incidence liver histology and outcome. Journal of acquired immune deficiency syndromes 32: 259-267.
Nunez MJ, Martin-Carbonero L, Moreno V, Valencia E, Garcia-Samaniego J, Gonzalez-Castillo J, Barreiro P, Gonzales-Lahoz J and Soriano V
(2006). Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. AIDS Research Human Retroviruses 22:825-829.
Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R and Snydman DR (2001). Increasing mortality due to end-stage liver disease in patients with HIV-infection. Clinical Infectious Diseases 32:492-497.
Nunez M (2006). Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Journal of hepatology 44: S132-139.
World Health Organisation (2013). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV-Infection.
Recommendations for a public health approach. www.who.int. Accessed January 18, 2015.
Soriano V, Puoti M, Garcia-Gasco P, Rockstroh JK, Benhamou Y, Barreiro P and McGovern B (2008).Antiretroviral drugs and liver injury.
AIDS 22(1): 1-3.
Kaplowitz N (2004). Drug-induced liver injury. Clinical Infectious Diseases 38(2): 44-48.
Raosoft Inc. 2004. Sample size calculator. Retrieved Aug. 30, 2015, from www.raosoft.com/samplesize.html. Accessed
May 23, 2015.
Laurent M, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Be´nifla JL, Burgard M, Lachassine E, Barret B, Chaix M, Bongain A, Ciraru-Vigneron N, Crenn-He´bert C, Delfraissy J, Rouzioux C and Mayaux M (2001). Lamivudine-Zidovudine combination for prevention of maternal-infant transmission of HIV-1. Journal of American Medical Association 285(16): 2083-2093.
Department of Health and Human Services (DHHS) (1991). Protection of human subjects. Code of Federal Regulations 45 CFR 46 Subpart DAdditional DHHS Protections for Children involved as Subjects in Research. (Department of Health and Human Services, National Institutes of Health, Office for Protection from Research Risks, Rockville, MD). Accessed June 18, 2014.
Laughon MM, Benjamin Jr DK, Capparelli EV, Kearns GL, Berezny K, Paul IM, Wade K, Barett J, Smith PB and Cohen-Wolkowiez M (2011).
Innovative clinical trial design for pediatric therapeutics. Expert Review of Clinical Pharmacology 4(5):643-652.
Tabor E (2009). FDA requirements for clinical studies in pediatric patients. Regulatory Focus 14:16-21.
Melo-Martin I, Sondhi D and Crystal RG (2011). When ethics constrains clinical research: trial design of control arms in “greater than minimal risk” pediatric trials. Human Gene Therapy 22:1121-1127.
Ouyang DW, Shapiro DE, Lu M, Brogly SB, French AL, Leighty RM, Thompson B, Tuomala RE, and Hershow RC (2009). Increased risk of
hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS 23(18): 2425–2430.
Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, Djedje M, Farquhar C (2007). Antiretroviral-associated toxicity among HIV-1-
seropositive pregnant women in Mozambique receiving nevirapine-based regimens. Journal of Acquired Immune Deficiency Syndrome 44(4): 371-376.
Ugiagbe RA, Malu AO, Bojuwoye BJ and Onunu AN (2012). Incidence of hepatotoxicity of highly active antiretroviral therapy in tertiary health center in Nigeria. Nigeria postgradraduate Medical Journal 19(3): 127-132.
Heylen R and Miller R (1997). Adverse effects ofmedications commonly used in the treatment of adult HIV-positive patients: Part 2. Genitourinary Medicine 73: 5-11.
Parker ME, Bentley ME, Chasela C, Adair L, Piwoz EG, Jamieson DJ, Ellington S, Kayira D, Soko A, Mkhomawanthu C, Tembo M, Martinson F and van der Horst C (2011). The acceptance and feasibility of replacement feeding at 6 months as an HIV prevention method in Lilangwe, Malawi: results from the BAN study. AIDS education and prevention 23(3): 281-285.
Nunez M and Soriano V (2005). Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. Drug safety 281: 53-66.
Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjananit S, Wannarit P, Sirisanthana T and Sirisanthana V (2007). Hospitalization and
mortality among HIV-infected children after receiving HAART. HIV/AIDS Clinical Infectious Diseases 44: 599-604.